Education
About Us
Working with TipRanks
Follow Us
Teva Pharmaceutical (TEVA)
NYSE:TEVA
TEVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.51 - $22.80
Previous CloseN/A
Volume1.13M
Average Volume (3M)12.12M
Market Cap
$18.38B
Enterprise Value$40.18B
Total Cash (Recent Filing)$3.30B
Total Debt (Recent Filing)$18.08B
Price to Earnings (P/E)―
Beta0.43
Next Earnings
May 07, 2025EPS Estimate
0.49Last Dividend Ex-Date
Nov 27, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-1.45
Shares Outstanding1,145,838,700
10 Day Avg. Volume11,779,839
30 Day Avg. Volume12,123,654
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.10
Price to Cash Flow (P/CF)7.90
P/FCF Ratio1.50
Enterprise Value/Market Cap2.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.98
Enterprise Value/Ebitda52.19
Forecast
1Y Price Target
$24.00Price Target Upside49.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Growth PotentialTeva can re-accelerate bottom line growth driven by three high value brands poised to launch with competitive profiles.
Revenue GrowthHigh margin brands like Austedo and Ajovy are expected to add significant sales, offsetting future headwinds.
ValuationTeva is considered undervalued relative to its medium to long-term growth outlook, leading to a Buy rating and a price objective of 23 USD.
Bears Say
Competitive PressureTeva flagged uncertain competitive dynamics as a net pricing variable for generics, particularly g-Revlimid.
EBITDA ChallengesRevising and lowering EBITDA estimates due to Gx Revlimid profitability concerns.
Market CompetitionTEVA will be 6-12 months behind the next closest TL1a competitor with a planned Phase 3 program start.
---
Ownership Overview
0.45% Insiders
7.41% Mutual Funds
30.73% Other Institutional Investors
58.10% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TEVA FAQ
What was Teva Pharmaceutical’s price range in the past 12 months?
Teva Pharmaceutical lowest stock price was $12.51 and its highest was $22.80 in the past 12 months.
What is Teva Pharmaceutical’s market cap?
Teva Pharmaceutical’s market cap is $18.38B.
When is Teva Pharmaceutical’s upcoming earnings report date?
Teva Pharmaceutical’s upcoming earnings report date is May 07, 2025 which is in 43 days.
How were Teva Pharmaceutical’s earnings last quarter?
Teva Pharmaceutical released its earnings results on Jan 29, 2025. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.707 by $0.003.
Is Teva Pharmaceutical overvalued?
According to Wall Street analysts Teva Pharmaceutical’s price is currently Undervalued.
Does Teva Pharmaceutical pay dividends?
Teva Pharmaceutical pays a Quarterly dividend of $0.072 which represents an annual dividend yield of N/A. See more information on Teva Pharmaceutical dividends here
What is Teva Pharmaceutical’s EPS estimate?
Teva Pharmaceutical’s EPS estimate is 0.49.
How many shares outstanding does Teva Pharmaceutical have?
Teva Pharmaceutical has 1,145,838,700 shares outstanding.
What happened to Teva Pharmaceutical’s price movement after its last earnings report?
Teva Pharmaceutical reported an EPS of $0.71 in its last earnings report, beating expectations of $0.707. Following the earnings report the stock price went down -13.888%.
Which hedge fund is a major shareholder of Teva Pharmaceutical?
Currently, no hedge funds are holding shares in TEVA
---
Teva Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.00 (49.07% Upside)
$24.00 (49.07% Upside)
Blogger Sentiment
Bullish
TEVA Sentiment 84%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 314.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $9.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
17.09%
12-Months-Change
Fundamentals
Return on Equity
-25.44%
Trailing 12-Months
Asset Growth
-9.55%
Trailing 12-Months
Company Description
Teva Pharmaceutical
Teva Pharmaceutical Industries Ltd. (TEVA) is a global leader in the pharmaceutical industry, specializing in the development, production, and marketing of generic medicines and a portfolio of specialty medicines. Headquartered in Israel, Teva operates in numerous countries worldwide, providing a wide range of products across various therapeutic areas including central nervous system, respiratory, oncology, and pain management. The company is particularly renowned for its significant presence in the generics market, leveraging its extensive research and development capabilities to deliver high-quality, affordable medications.
---
TEVA Company Deck
---
TEVA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected a strong performance in key products and business segments, alongside improvements in credit ratings, but also highlighted challenges such as the impact of macroeconomic factors and the future decline in Revlimid revenue. Despite these challenges, Teva remains optimistic about its growth strategy and product pipeline.Read More>---
TEVA Revenue Breakdown
54.45% North America
32.42% Europe
13.12% International Markets
---
TEVA Stock 12 Month Forecast
Average Price Target
$24.00
▲(49.07% Upside)
Technical Analysis
Best Analysts Covering TEVA
1 Year
1 Year Success Rate
12/25 ratings generated profit
1 Year Average Return
+17.47%
reiterated a buy rating 28 days ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 48.00% of your transactions generating a profit, with an average return of +17.47% per trade.
---